Lung Cancer Genomic Testing Market Size, Share, Trends & Forecast

The Lung Cancer Genomic Testing Market is expanding as genomic information becomes increasingly important in cancer diagnosis and personalized treatment. Demand is being supported by the growing prevalence of lung cancer, advances in molecular testing, and wider adoption of targeted therapies. Genomic testing helps identify clinically relevant biomarkers and genetic alterations that can support treatment planning and patient stratification.

Next-generation sequencing is becoming an important technology within the market because it can examine multiple genetic alterations from a single sample. PCR, in situ hybridization, and other molecular techniques also contribute to the testing landscape. Liquid biopsy is gaining attention because blood-based samples can provide a less invasive approach to obtaining tumor-related genetic information.

The major testing applications include biomarker testing and genetic analysis, with growing interest in companion diagnostics for targeted and immunotherapy-based treatments. Tissue samples remain important, while blood samples are creating additional opportunities for minimally invasive testing. Hospitals, diagnostic laboratories, and research centers are key end users of these technologies.

North America represents a major regional market, supported by advanced healthcare infrastructure, high research investment, and strong adoption of precision medicine. Europe also has an established testing ecosystem, while Asia-Pacific offers considerable expansion potential as healthcare expenditure, cancer awareness, and access to advanced diagnostic technologies increase.

The future of lung cancer genomic testing is likely to be shaped by artificial intelligence, improved sequencing platforms, liquid biopsy, and more comprehensive biomarker analysis. Greater integration between genomic results and clinical decision-support systems could help laboratories and physicians manage increasingly complex datasets. Continued expansion of personalized medicine is expected to create further opportunities for genomic testing providers.